Ambrosini A, de Noordhout A und Sandor PS and Schoenen J (2003): Electrophysiological
studies in migraine: a comprehensive review of their interest and limitations. Cephalalgia causes high intensity dependence of auditory evoked cortical potentials in migraine. Brain 126, 2009-2015 Ashina M, Bendtsena L, Jensena R, Schifterb S and Olesen J (2000): Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain 86, 133-138 Barbiroli B, Montagna P, Cortelli P, Funicello R, Iotti S, Monari L et al (1992): Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology 1209, 115–1214 a (2004): Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann. Neurol. 56, 371-381 Battelli L, Black KR und Wray SH (2002): Transcranial magnetic stimulation of visual area V5 in migraine. Neurology 58, 1066–1069 Bellamy J, Bowen E, Russo A and Durham P (2006): Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons. Eur. J. Neurosci. 23, 2057–2066 Bocos C, Gottlicher M, Gearing K, Banner C, Enmark E, Teboul M et al (1995): Fatty acid activation of peroxisome proliferator-activated receptor (PPAR). J. Steroid. Biochem. Mol. Biol. 53, 467–473 Bough KJ und Rho JM. Anticonvulsant mechanisms of the ketogenic diet (2007): Epilepsia Bough KJ, Wetherington J, Hassel B, Pare JF, Gawryluk JW, Greene JG et al (2006): Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann. Neurol. 60, 223–235 Buchanan TM and Ramadan NM (2006): Prophylactic pharmacotherapy for migraine aspects of regulation of mitochondrial activity by fenofibrate and fasti 482, 71-74 arcia Y, Plotkine M and Marchand-Leroux C (2007): Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. 24, 1119-1131 Chung SW, Kang BY, Kim SH, Pak YK, Cho D, Trinchieri G et al (2000): Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. J. Biol. Chem. 275, 32681–32687 ketogenic diet in children, adolescents and young adults with refractory epilepsy: an Italian multicentric experience 48, 221-227 Cullingford TE, Bhakoo K, Peuchen S a (1998): Distribution of mRNAs encoding the peroxisome proliferator-activated receptor (PPAR) - Ketogenic diet in migraine – a new approach for treatment ? alpha, -beta, and -gamma and the retinoid X receptor (RXR) -alpha, -beta, and -gamma in rat central nervous system. J. Neurochem. 70, 1366-1375 Cullingford TE, Eagles DA and Sato H (2002): The ketogenic diet upregulates expression of the gene encoding the key ketogenic enzyme mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase in rat brain. Epilepsy Res. 49, 99-107 D'Amico D, Ferraris A, Catania A, Carlin A, Leone M, Attanasio A and Bussone G (1998): Increased basal nitric oxide plasma concentration in migraine. EOS 13, 109-111 Dahlin M, Elfving A, Ungerstedt U and Amark P (2005): The ketogenic diet influences the levels of excitatory and inhibitory amino acids in the CSF in children with refractory epilepsy. Epilepsy Res. 48, 115-125 Delerive P, De Bosscher K, Vanden Berghe W, Fruchart JC, Haegeman G and Staels B (2002): DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. Mol. Endocrinol. 16, 1029 –1039 Delerive P, Gervois P, Fruchart JC and Staels B (2000): Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J. Biol. Chem. 275, 36703–36707 Dodick D und Silberstein S (2006): Central sensitization theory of migraine: clinical Dodick DW and Silberstein SD (2007): Migraine prevention. Pract .Neurol. 7, 383–393 De Vivo DC, Leckie MP, Ferrendelli JS and McDougal DB (1978): Chronic ketosis and cerebral metabolism. Ann. Neurol. 3, 331-337 Ebersberger A (2002): Pathophysiologie der Migräne. Anaesthesist 5, 661–667 Escher P and Wahli W (2000): Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat. Res. 448, 121–138 Forman BM, Chen J and Evans RM (1997): Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. USA 94, 4312–4317 Freeman JM, Kossoff EH and Hartman AL (2007): The ketogenic diet: one decade later. Fuenmayor LD and Garcia S (2002): The effect of fasting on 5-hydroxytryptamine metabolism in brain regions of the albino rat. Br J Pharmacol 1984; 83: 375-362 Fusayasu E , Kowa H, Takeshima T, Nakaso K and Nakashima K (2007): Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain 128, 209–214 Goadsby PJ, Lipton RB and Ferrari MD (2002): Migraine - current understanding and treatment. N. Engl. J. Med. 346, 257-270 Gutschalk A, Kollmar F, Mohr A, Henze M, Ille N, Schwaninger M et al (2002): Multimodal functional imaging of prolonged neurological deficits in a patient suffering from familial hemiplegic migraine. Neurosci. Lett. 332, 115–118 Hasselbach SG, Knudsen GM, Jakobsen J, Hageman LP, Holm S and Paulson OB (1994): Brain metabolism during short-term starvation in humans. 14, 125–131 Issemann I and Green S (2002): Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645–650 Jabre MG and Bejjani BP (2006): Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology 66, 617 Ketogenic diet in migraine – a new approach for treatment ? Jacome DE (2001): Hypoglycemia rebound migraine. Headache 41, 895–898 Juge-Aubry C, Pernin A, Favez T, Burger AG, Wahli W, Meier CA et al (1997): Desvergne,
DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 50-flanking region. J. Biol. Chem. 272, 25252–25259 (2007): The triggers or precipitants of the acute migraine attac 27, peroxisome proliferator-activated receptor alpha regulates amino acid metabolism. 15, 1971-1978 therapy for intractable epilepsy. Neurology 23, 1789-1791 modified Atkins diet is effective for the treatment of intractable pediatric epilepsy. Epilepsia 47, 421-424 Lang E, Kaltenhäuser M, Neundörfer B and Seidler S (2004): Hyperexcitability of the primary somatosensory cortex in migraine - a magnetoencephalographic study. Brain 127, 2459–2469 Latruffe N, Cherkaoui-Malki M, Nicolas-Frances V, Clemencet MC, Janin B and Berlot J (2000): Regulation of the peroxisomal β-oxidation-dependent pathway by peroxisome proliferator-activated receptor α and kinases. Biochem. Pharmacol. 60, 1027–1032 Le May C, Pineau T, Bigot K, Kohla C, Girarda J and Pégorier JP (2000): Reduced hepatic fatty acid oxidation in fasting PPARalpha null mice is due to impaired mitochondrial hydroxymethylglutaryl-CoA synthase gene expression. FEBS letters 475, 163-166 Leonardi M, Steiner T, Scher AT and Lipton RB (2005): The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). J. Headache Pain 6, 429–440 Leone TC, Weinheimer CJ and Kelly, DP (1999): A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc. Natl. Acad. Sci. USA 96, 7473-7478 Kantak KM, Wayner MJ and Stein JM (1978): Effects of various periods of food deprivation on serotonin synthesis in the lateral hypothalamus. Pharmacol Biochem Behav. 9, 534-541 ketogenic diet: adolescents can do it, too. Epilepsia 44, 847-851 Magisretti P and Pellerin L (1999): Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 354, 1155-1163 Margareta T, Nehlig A and Sonnewald U (2006): Neuronal-glial interactions in rats fed a ketogenic diet. Neurochem. Int .48, 498-507 Marsters JB, Mortimer MJ and Hay KM (1986): Glucose and diet in the fasting migraineur. Mattson MP, Duan W and Guo Z (2003): Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms. J. Neurochem. 84, 417–431 Ketogenic diet in migraine – a new approach for treatment ? Matsutani K, Tsuruoka, M, Shinya A, Furuya R and Kawawa T (2000): Stimulation of the locus coeruleus suppresses trigeminal sensorimotor function in the rat. Brain. Res. Bull. 53, 827-832; zit in: Peroutka 2004 McCarthy LC, Hosford DA, Riley JH, Bird MI, White NJ, Hewett DR et al (2001): Single- nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomoics 78, 135–149 Montagna P, Cortelli P, Monari L, Pierangeli G, Parchi P, Lodi R et al (1994): 31P-magnetic resonance spectroscopy in migraine without aura. Neurology 44, 666–669 Moskowitz MA, Bolay H and Dalkara T (2004): Deciphering migraine mechanisms: clues from familial hemiplegic migraine genotypes. Ann. Neurol. 55, 276–280 Neubauer G and Ujlaky RP (2002): Migräne - eine Volkskrankheit und ihre Kosten. Pharm Pan JW, Bebin EM, Chu WJ and Hetherington HP (1999): Ketosis and Epilepsy: 31P Spectroscopic imaging at 4.1 T. Epilepsia 40, 703–707 Peroutka S (2004): Migraine: a chronic sympathetic nervous sytem disorder. Headache 44, a(2005): Low-glycemic-index treatment: a liberalized ketogenic diet for treatment of intractable epileps 65, 1810-1812 Pirke KM, Broocks A, Wilckens R a U (1993): Starvation-induced hyperactivity in the rat: the role of endocrine and neurotransmitter changes. Neurosci. Biobehav. Rev .17, 287-294 (1997): Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig). Cephalalgia 17, 849-854 Sacquegna T, Lodi R, De Carolis P, Tinuper P, Cortelli P, Zaniol P et al (1992): Brain energy metabolism studied by 31P-MR spectroscopy in a case of migraine with prolonged aura. Acta Neurol. Scand. 86, 376–380 Sakai Y, Dobson C, Diksic M, Aubé M and Hamel E (2008): Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis. Neurology 70, 431-439 Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG and Smith TR et al (2004): LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 24, 596–602 Sankar R and Sotero de Menezes M (1999): Metabolic and endocrine aspects of the ketogenic Sasa M, Fujimoto S, Igarashi S, Munekiyo K and Takaori S (1979): Microiontophoretic studies on noradrenergic inhibition from locus coeruleus of spinal trigeminal nucleus neurons. J. Pharmacol. Exp. Ther. 210, 311-315; zit in: Peroutka 2004 Schwartz MW, Figlewicz DP, Baskin DG, Woods SC, Porte D Jr et al (1992): Insulin in the brain: a hormonal regulator of energy balance. Endocr. Rev. 13, 387–414 Schweiger U, Broocks A, Tuschl RJ and Pirke KM (1989): Serotonin turnover in rat brain during semistarvation with high protein and high carbohydrate diets. J. Neural. Transm. 77, 131-139 Sethi S, Ziouzenkova O, Wagner DD, Plutzky J and Mayadas TN (2002): Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha. Blood 100, 1340–1346 Ketogenic diet in migraine – a new approach for treatment ? Shalev A, Siegrist-Kaiser CA, Yen PM, Whali W, Burger AG, ChinWW and Meier CA (1996): The peroxisome proliferator-activated receptor a is a phosphoprotein: regulation by insulin. Endocrinology 137, 4499–4502 Sheikh K, Camejo G, Lanne B, Halvarsson T, Landergren MR and Oakes ND (2007): Beyond lipids, pharmacological PPAR-activation has important effects on amino acid metabolism as studied in the rat. Am. J. Physiol. Endocrinol. Metab. 292, 1157–1165 Shields KG and Goadsby PJ (2006): Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: A migraine target? Neurobiol. Dis. 23, 491– 501 Silberstein SD (2004): Migraine. Lancet 363, 381–391 Silver IA and Erecinsyca M (1997): Energetic demands of the Na/K ATPase in mammalian diet for intractable epilepsy in adults: preliminary results. Epilepsia 40, 1721-1726 Sparaco M, Feleppa M, Lipton RB, Rapoport AM and Bigal ME (2006): Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia 26, 361–372 Storer RJ, Akerman S, Shields KG and Goadsby PJ (2004): GABAA receptor modulation of trigeminovascular nociceptive neurotransmission by midazolam is antagonized by flumazenil. Brain Res.1013, 188–193 Strahlman RS (2006): Can ketosis help migraine sufferers? A case report. Headache 46, 182– Sullivan PG, Rippy NA, Dorenbos K, Concepcion RC, Agarwal AK and Rho JM (2004): The ketogenic diet increases mitochondrial uncoupling protein levels and activity. Ann. Neurol. 55, 576–580 Szot P, Weinshenker D, Rho JM, Storey TM and Schwartzkroin PA (2001): Norepinephrine is required for the anticonvulsant effect of the ketogenic diet. Brain Res. Dev. Brain. Res. 129, 211–214 Taha AY, Ryan MA and Cunnane SC (2005): Despite transient ketosis, the classic high-fat ketogenic diet induces marked changes in fatty acid metabolism in rats. Metabolism 54, 1127–1132 Taha A, Ryan M and Cunnane S (2005): Despite transient ketosis, the classic high-fat ketogenic diet induces marked changes in fatty acid metabolism in rats. Metabolism 54, 1127– 1132 Theodore WH (2003): Does serotonin play a role in epilepsy? Epilepsy Curr. 3, 173–177 Van der Auwera I, Wera S, Van Leuven F and Henderson ST (2005): A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer’s disease. Nutr. Metab. (Lond.) 2, 28 Volek JS, Sharman MJ, Love D, Avery N, Scheett AG and Kraemer W (2002): Body composition and hormonal responses to a carbohydrate restricted diet. Metabolism 51, 864–870 Weiyuan M, Berg J and Yellen G (2007): Ketogenic diet metabolites reduce firing in central neurons by opening KATP channels. J. Neurosc. 27, 3618-3625 Welch KM (2005): Brain hyperexcitability: the basis for antiepileptic drugs in migraine Ketogenic diet in migraine – a new approach for treatment ? Welch KM, Levine SR, D'Andrea G, Schultz LR, Helpern JA (1989): Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology 39, 538–541 Wolf NI, Bast T and Surtees R (2005): Epilepsy in inborn errors of metabolism. Epileptic. Xiao DQ, Zhua JX, Tanga JS and Jia H (2005): GABAergic modulation mediates antinociception produced by serotonin applied into thalamic nucleus submedius of the rat. Brain Research 1057, 161 – 167 Xu J, Storer P, Chavis J, Racke M and Drew P (2005): Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. J. Neurosci. Res. 81, 403–411 Yudkoff M, Daikhin Y, Nissim I, Grunstein R and Nissim I (1997): Effects of ketone bodies on astrocyte amino acid metabolism. J. Neurochem. 69, 682-692 Yudkoff M, Daikhin Y, Nissim I, Lazarow A, Nissim I (2001): Ketogenic Diet, amino acid metabolism, and seizure control. J. Neurosci. Res. 66: 931–940 Ziegler DR, Ribeiro LC, Hagenn M, Siqueira IR, Araújo E, Torres IL et al (2003): Ketogenic diet increases glutathione peroxidase activity in rat hippocampus. Neurochem. Res. 28, 1793–1797 Zhao Z, Lange DJ, Voustianiouk A, MacGrogan D, Ho L, Suh J et al (2006): A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci. 7, 29


Bula - fluconazol med genérico rev 03

fluconazol medicamento genérico - lei nº 9.787, de 1.999 SISTEMA FECHADO Formas farmacêuticas e apresentações: Solução para infusão intravenosa: Embalagem contendo 01 bolsa plástica com 100 mL (2 mg/mL). USO ADULTO E PEDIÁTRICO Solução para infusão intravenosa: USO INTRAVENOSO. Composição: Cada mL de Fluconazol genérico infusão intravenosa contém 2 mg de flu

Microsoft word - bone disease, voskaridou.doc

MANAGEMENT OF THALASSAEMIA-INDUCED OSTEOPOROSIS Ersi Voskaridou, MD, PhD; Evangelos Terpos, MD, PhD Thalassaemia Centre, Laikon General Hospital, Athens, Greece N.B. This is an extract from the presentation given by Dr Voskaridou at our conference on 14.6.05. A complete version, including a full list of references is available on request from the UKTS office. Prevention and general principle

© 2010-2017 Pharmacy Pills Pdf